ONTX - オンコノバ・セラピュ―ティクス (Onconova Therapeutics Inc.) オンコノバ・セラピュ―ティクス

 ONTXのチャート


 ONTXの企業情報

symbol ONTx
会社名 Onconova Therapeutics Inc (オンコノバ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 オンコノヴァ・セラピューティクス(Onconova Therapeutics Inc.)は臨床段階のバイオ医薬品会社であり、がん治療用の小分子薬剤候補の発見・開発に取り組む。同社が作成した標的抗がん剤は、がんを促進する特定の細胞経路に対して機能するように設計される。同社は3つの臨床段階の製品候補と6つの前臨床プログラムを有する。同社の前臨床パイプラインはキナーゼ、細胞代謝や分裂を標的にする6つのプログラムを含む。   オンコノバ・セラピュ―ティクスは米国のバイオテクノロジ―会社。がん治療の小分子医薬品候補の発見と開発に従事する。主に臨床期向け治療薬の開発に注力。臨床検査段階の治療薬候補には、骨髄異形成症候群および頭頚部がん用の「リゴサチブ」、急性放射線症候群用の「recilisib」などがある。   Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
本社所在地 375 Pheasant Run Newtown PA 18940 USA
代表者氏名 Michael M. B Hoffman マイケル・M・ホフマン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 267-759-3681
設立年月日 36130
市場名 NASDAQ Small Cap
ipoyear 2013年
従業員数 36人
url www.onconova.com
nasdaq_url https://www.nasdaq.com/symbol/ontx
adr_tso
EBITDA EBITDA(百万ドル) -24.34600
終値(lastsale) 5.92
時価総額(marketcap) 33590944.32
時価総額 時価総額(百万ドル) 33.76100
売上高 売上高(百万ドル) 1.30200
企業価値(EV) 企業価値(EV)(百万ドル) 4.22100
当期純利益 当期純利益(百万ドル) -22.85700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Onconova Therapeutics Inc revenues increased 96% to $1M. Net loss decreased 12% to $9.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income net increase from $11K to $112K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$22.78 to -$6.14.

 ONTXのテクニカル分析


 ONTXのニュース

   Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET …
   Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020  2020/08/07 12:00:00 GlobeNewswire
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12
   Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis  2020/07/29 17:30:00 GlobeNewswire
Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020
   Onconova files for NIH funding for studies of rigosertib in COVID-19 (NASDAQ:ONTX)  2020/07/27 12:25:37 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID) aimed at obtaining fun
   Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease  2020/07/27 12:00:00 Yahoo Finance
Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replicationNEWTOWN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products
   Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020  2020/08/07 12:00:00 GlobeNewswire
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12
   Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis  2020/07/29 17:30:00 GlobeNewswire
Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020
   Onconova files for NIH funding for studies of rigosertib in COVID-19 (NASDAQ:ONTX)  2020/07/27 12:25:37 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID) aimed at obtaining fun
   Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease  2020/07/27 12:00:00 Yahoo Finance
Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replicationNEWTOWN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products
   Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar  2020/06/23 12:00:00 GlobeNewswire
NEWTOWN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on…
   Onconova Therapeutics (ONTX): FY2019 Earnings Snapshot  2020/03/25 12:28:03 news.alphastreet.com
— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. — Net loss was $21.5 million compared to $20.4 million last year. — Research and development expenses were $15.5 million versus $16.9 million for 2018. — Cash and cash equivalents as of December 31, 2019, totaled […]
   Onconova (ONTX) to Report Q4 Earnings: What's in Store?  2020/03/02 14:54:00 Zacks Investment Research
Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.
   Onconova regains rigosertib rights in China; shares up 17% premarket  2020/01/23 14:17:57 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) is up 17% premarket on robust volume in reaction to its announcement that it has regained the rights to rigosertib in G
   Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market  2019/12/31 16:30:00 GlobeNewswire
NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage…
   Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering  2019/11/25 14:26:03 GlobeNewswire
Offering led by healthcare dedicated funds, including Knight Therapeutics Inc., along with officers and directors of Onconova

 関連キーワード  (医薬品 米国株 オンコノバ・セラピュ―ティクス ONTX Onconova Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)